3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
6
Leukemia
5
Neoplasms by Histologic Type
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Carcinoma, Non-Small-Cell Lung
4
Bone Marrow Diseases
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myeloid, Chronic-Phase
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Adenocarcinoma of Lung
1
Interventions
Oxaliplatin
4
Leucovorin
4
Irinotecan
4
Fluorouracil
4
Capecitabine
3
Bevacizumab
3
cobimetinib
2
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Standard of Care
2
Specimen Handling
2
Panitumumab
2
Magnetic Resonance Spectroscopy
2
Ketamine
2
Hydroxychloroquine
2
Cyclophosphamide
2
Cisplatin
2
ulixertinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tivozanib
1
sodium thiosulfate
1
rucaparib
1
romiplostim
1
rilotumumab
1
regorafenib
1
pralsetinib
1
ponatinib
1
pembrolizumab
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts